As a health company, we envision empowering global well-being by pioneering biological solutions drawn from nature.
Our mission: Unlock the full potential of exDNA across diverse indications. Our AND Technology Platform has the primary focus on controlling disease caused by pathogenic bacteria.
Cooperation possibilities
We are open for collaborations in the field of Research and pre-clinical stage development. We are also open to discuss funding opportunities.
- http://www.anbiotech.com
- Send an email
- Marc-Olivier Zwicky
Some insights
We believe there is a new way to develop medicines going forward by using the pathogens themselves as the solution. This would pioneer how we think we develop solutions for patients fundamentally.
We are pioneering how we use extracellular DNA for the fight against nasty bacteria! In our young journey, we can say we have will hit first clinical candidates withing the next 12 months!
Moderna with they pivot platform shift towards vaccines. Their approach for flexibility in their platform has shown crucial for their company and people.
BioVersys is on a critical path to solve some of the biggest AMR challenges. Their advancements fighting resistance is impressive.
We have a pragmatic and flexible approach where we combine not only science, but a lot of commercial strategic thinking from the start.
We are looking for drug developers who have experience in rare tropical diseases.
I play with bacteria to help people get better.
Drug Development Expertise.
Funding.
Partners who can educate the world on our approach.
Business Development Experts.
Scientific Drug Developers.